The nephropathy was successfully treated with tocilizumab, suggesting that IL-6 may cause diabetic nephropathy-like and/or arteriosclerotic-like nephropathy in patients with hypolipidemia, normal-range blood pressure, and normal glycemia. This evidence concerns the gene IL6 and diabetic kidney disease.